



Taclonex[®] (betamethasone dipropionate/calcipotriene) – First-time authorized brand alternative

- On January 20, 2020, Prasco launched an authorized brand alternative of LEO Pharma's [Taclonex \(betamethasone dipropionate/calcipotriene\)](#) topical suspension.
- Taclonex is approved for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older.
- Betamethasone dipropionate/calcipotriene is also available generically as an [ointment](#) that is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.